Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
Marksans Pharma Management
Management Kriterienprüfungen 1/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Mark Saldanha
Geschäftsführender
₹52.2m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 92.0% |
| Amtszeit als Geschäftsführer | 8.6yrs |
| Eigentum des Geschäftsführers | 43.8% |
| Durchschnittliche Amtszeit des Managements | keine Daten |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 5.8yrs |
Jüngste Management Updates
This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16
What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06
Recent updates
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Nov 04If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Oct 20Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?
Oct 05If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns
Sep 20A Look At The Fair Value Of Marksans Pharma Limited (NSE:MARKSANS)
Aug 20Many Still Looking Away From Marksans Pharma Limited (NSE:MARKSANS)
Aug 05If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Jul 08Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | ₹3b |
| Sep 30 2023 | n/a | n/a | ₹3b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹52m | ₹48m | ₹3b |
| Dec 31 2022 | n/a | n/a | ₹2b |
| Sep 30 2022 | n/a | n/a | ₹2b |
| Jun 30 2022 | n/a | n/a | ₹2b |
| Mar 31 2022 | ₹38m | ₹35m | ₹2b |
| Dec 31 2021 | n/a | n/a | ₹2b |
| Sep 30 2021 | n/a | n/a | ₹2b |
| Jun 30 2021 | n/a | n/a | ₹3b |
| Mar 31 2021 | ₹10m | ₹10m | ₹2b |
| Dec 31 2020 | n/a | n/a | ₹2b |
| Sep 30 2020 | n/a | n/a | ₹2b |
| Jun 30 2020 | n/a | n/a | ₹1b |
| Mar 31 2020 | ₹10m | ₹10m | ₹1b |
| Dec 31 2019 | n/a | n/a | ₹879m |
| Sep 30 2019 | n/a | n/a | ₹834m |
| Jun 30 2019 | n/a | n/a | ₹780m |
| Mar 31 2019 | ₹10m | ₹10m | ₹804m |
| Dec 31 2018 | n/a | n/a | ₹666m |
| Sep 30 2018 | n/a | n/a | ₹582m |
| Jun 30 2018 | n/a | n/a | ₹463m |
| Mar 31 2018 | ₹12m | ₹10m | ₹358m |
Vergütung im Vergleich zum Markt: MarkDie Gesamtvergütung ($USD627.92K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Indian ($USD382.73K).
Entschädigung vs. Einkommen: MarkDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.
Geschäftsführer
Mark Saldanha (51 yo)
8.6yrs
Amtszeit
₹52,161,600
Vergütung
Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Non-Independent Executive Chairman & MD | 8.6yrs | ₹52.16m | 43.8% ₹ 33.0b | |
| Whole-time Director | 9.7yrs | ₹7.03m | 0.049% ₹ 36.6m | |
| Whole-time Director | 5.3yrs | ₹15.25m | keine Daten | |
| Non-Executive Director & Non-Independent | 2.8yrs | keine Daten | keine Daten | |
| Non-Executive & Independent Director | 4.8yrs | ₹40.00k | keine Daten | |
| Independent Director | less than a year | keine Daten | keine Daten | |
| Non-Executive & Independent Director | 12.6yrs | ₹40.00k | keine Daten | |
| Non-Executive Independent Director | 6.2yrs | ₹200.00k | keine Daten |
5.8yrs
Durchschnittliche Betriebszugehörigkeit
52.5yo
Durchschnittliches Alter
Erfahrener Vorstand: MARKSANSDie Vorstandsmitglieder gelten als erfahren (5.8 Jahre durchschnittliche Amtszeit).